Jeremy Goldhaber-Fiebert and his colleagues found that treating hepatitis-C-infected inmates with a drug that costs more than $7,000 per week is cost-effective compared with other approved treatments.
Steve Fisch
Jeremy Goldhaber-Fiebert and his colleagues found that treating hepatitis-C-infected inmates with a drug that costs more than $7,000 per week is cost-effective compared with other approved treatments.
Steve Fisch